Urocortin 2 increases c-Fos expression in serotonergic neurons projecting to the ventricular/periventricular system.
Serotonin plays an important role in the regulation of anxiety states and physiological responses to aversive stimuli. Intracerebroventricular (i.c.v.) injection of the stress- and anxiety-related neuropeptide urocortin 2 (Ucn 2) increases c-Fos expression in serotonergic neurons in the dorsal (DRD) and caudal (DRC) parts of the dorsal raphe nucleus. These regions contain a subset of serotonergic neurons that projects via the dorsal raphe periventricular tract to periventricular structures, including the subfornical organ and ependymal layer, and to the ventricular system. To determine if Ucn 2 activates ventricle/periventricular-projecting serotonergic neurons in the midbrain raphe complex, we made i.c.v. injections of the retrograde tracer Fluoro-Gold into the lateral ventricle, followed 7 days later by i.c.v. injection of Ucn 2. The DRD at -8.18 mm and the DRC at -8.54 mm and -9.16 mm bregma were analyzed using a combined bright field and immunofluorescence technique. Approximately 40% of the ventricle/periventricular-projecting neurons in the subdivisions sampled were serotonergic. Urocortin 2 increased c-Fos expression in ventricle/periventricular-projecting serotonergic neurons in the DRC and in non-ventricle/periventricular-projecting serotonergic neurons in the DRD and DRC. Of the total population of ventricle/periventricular-projecting serotonergic neurons in the DRC at -8.54 and -9.16 mm bregma, 35% expressed c-Fos following Ucn 2 injections. These data are consistent with previous studies showing that i.c.v. injection of Ucn 2 activates subpopulations of serotonergic neurons restricted to the mid-rostrocaudal DRD and DRC and further demonstrate that these include both subsets of serotonergic neurons that do and do not project to the ventricle/periventricular system.
Hale
Matthew W
MW
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, CO 80309-0354, USA. matthew.hale@colorado.edu
Stamper
Christopher E
CE
Staub
Daniel R
DR
Lowry
Christopher A
CA
D000704:Analysis of Variance; D000818:Animals; D002408:Catheters, Indwelling; D002452:Cell Count; D007150:Immunohistochemistry; D008297:Male; D056325:Neuronal Tract-Tracers; D009475:Neurons, Afferent / Q000187:drug effects* / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D011903:Raphe Nuclei / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012701:Serotonin / Q000378:metabolism*; D020542:Third Ventricle / Q000378:metabolism*; D014365:Tryptophan Hydroxylase / Q000378:metabolism; D054832:Urocortins / Q000494:pharmacology*
D056325:Neuronal Tract-Tracers; D016760:Proto-Oncogene Proteins c-fos; D054832:Urocortins; D012701:Serotonin; D014365:Tryptophan Hydroxylase
Neurochem Res. 2004 Sep;29(9):1739-47
15453270
Neuroscience. 2005;133(4):983-97
15916857
Brain Res. 1993 Oct 8;624(1-2):188-98
8252391
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20994-9
19095802
Neurosci Lett. 1997 Jul 11;230(1):57-60
9259463
J Comp Neurol. 1986 Jan 15;243(3):363-80
2419370
Neuropsychopharmacology. 2004 Mar;29(3):450-60
14872203
J Comp Neurol. 2004 Jun 28;474(3):364-78
15174080
Neuroscience. 2006 Aug 25;141(2):1047-1055
16713119
Eur J Pharmacol. 2008 Jan 14;578(2-3):185-93
17945210
Anat Histol Embryol. 2008 Feb;37(1):9-18
18197894
Anat Histol Embryol. 1999 Jul;28(3):193-7
10458025
J Comp Neurol. 1978 Jun 1;179(3):641-67
565370
Brain Res. 2002 Jul 5;943(1):142-50
12088848
J Neurochem. 2005 Jul;94(1):45-56
15953348
J Neurosci. 2003 Feb 1;23(3):1019-25
12574432
Acta Anat (Basel). 1989;134(4):319-21
2741661
Am J Psychiatry. 1997 Dec;154(12):1771-3
9396964
Neuropsychopharmacology. 1998 Jun;18(6):492-502
9571657
Peptides. 2004 Apr;25(4):659-66
15165722
Ann N Y Acad Sci. 2004 Jun;1018:58-64
15240352
J Physiol. 2001 Feb 15;531(Pt 1):131-40
11179397
Neuroscience. 1981;6(4):557-618
7017455
J Pharmacol Exp Ther. 2004 Sep;310(3):1027-34
15115804
Brain Res. 2006 Jan 27;1070(1):77-89
16403469
Nat Genet. 2000 Apr;24(4):410-4
10742108
Neuroscience. 2008 Dec 10;157(4):733-48
18951955
Neurosci Lett. 1977 Aug;5(5):297-302
19605010
J Pharmacol Exp Ther. 2002 Jul;302(1):145-52
12065711
J Comp Neurol. 1998 Sep 14;399(1):61-72
9725701
Brain Res. 2003 Feb 14;963(1-2):57-71
12560111
Nat Med. 2001 May;7(5):605-11
11329063
Ann N Y Acad Sci. 1997 Dec 29;836:158-81
9616798
Neuroscience. 1999;89(4):999-1002
10362289
J Psychiatry Neurosci. 1995 Jul;20(4):271-5
7544158
Pharmacopsychiatry. 1995 Mar;28(2):45-50
7542785
J Comp Neurol. 1997 Aug 11;384(4):556-68
9259489
J Neurosci. 2006 May 17;26(20):5500-10
16707802
J Neurosci. 2001 Apr 15;21(8):2833-41
11306635
Neurosci Lett. 1995 Jun 30;193(2):77-80
7478163
J Neurosci. 2004 Feb 11;24(6):1305-11
14960601
Brain Res. 2005 May 24;1044(2):176-89
15885216
Peptides. 2004 Oct;25(10):1703-9
15476937
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2843-8
11226328
Curr Opin Pharmacol. 2002 Feb;2(1):23-33
11786305
Biol Psychiatry. 1992 Jan 15;31(2):112-8
1371076
Nat Genet. 2000 Apr;24(4):403-9
10742107
Trends Pharmacol Sci. 2008 Sep;29(9):433-6
18585794
Biol Psychiatry. 1999 Nov 1;46(9):1181-91
10560024
Arch Gen Psychiatry. 2008 Jan;65(1):38-46
18180427
J Comp Neurol. 1981 Nov 1;202(3):335-56
7298902
Biol Psychiatry. 2001 Nov 15;50(10):783-91
11720697
Neuroscience. 2004;129(3):509-19
15541873
Neuropsychopharmacology. 2000 Feb;22(2):148-62
10649828
Cell. 1999 Jun 11;97(6):703-16
10380923
Anat Embryol (Berl). 1983;167(3):311-9
6354002
Science. 2003 Aug 8;301(5634):805-9
12907793
Neuroscience. 1998 Jan;82(2):443-68
9466453